Novel Injectable Gels for the Sustained Release of Protein C

  • Mahesh V. Chaubal
  • Zhong Zhao
  • Duane F. Bruley
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 540)

Abstract

Protein C is a vitamin K dependent protein present in the human blood plasma at a concentration of 4 µg/ml. The protein exists as a zymogen precursor of a serine protease and is an important component of the coagulation cascade. The activated form of protein C regulates the coagulation cascade preventing abnormal blood clots, thus maintaining a regular flow of blood and oxygen to tissues. Protein C deficiency, which affects up to 1 in 300 people in the general population (Nizzi and Kaplan, 1999), causes a lack of regulation of the natural blood coagulation pathway and could lead to massive thrombosis (clogging of blood vessels due to clots). Such clogging of blood vessels can further cause tissue oxygen deprivation resulting in tissue damage. Serious examples of this damage include stroke, heart attack, pulmonary embolism, tissue necrosis and other complications that can result in amputation or death.

Keywords

Ethyl DMSO Chitosan Heparin Coumadin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anderson BC, Pandit NK, Mallapragada SK. Understanding drug release from poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) gels. J Control Release; 70 (1-2): 157 - 67, 2000.Google Scholar
  2. Brodbeck KJ, Pushpala S, McHugh AJ. Sustained release of human growth hormone from PLGA solution depots. Pharm Res 16: 1825 - 9, 1999a.PubMedCrossRefGoogle Scholar
  3. Brodbeck KJ, DesNoyer JR, McHugh M. Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer. J Control Release; 62: 333 - 44, 1999b.PubMedCrossRefGoogle Scholar
  4. Bruley DF, Drohan WN (1990) Protein C and related anticoagulants. Advances in applied biotechnology series, Volume 11, Gulf Publishing Company.Google Scholar
  5. Burke PA. Controlled Release Protein Therapeutics: Effects of Process and Formulation on Stability. In “Handbook of Pharmaceutical Controlled Release Technology” Wise DL (Ed), p. 661–693, Marcel Dekker, New York, 2000.Google Scholar
  6. Chaubal MV, Zhao Z, Bruley DF. Evaluation of emulsion based microencapsulation processes for sustained release of protein C. AIChE Annual Meeting, Dallas, Texas Nov 1999.Google Scholar
  7. Einmahl S, Zignani M, Varesio E, Heller J, Veuthey JL, Tabatabay C, Gurny R. Concomitant and controlled release of dexamethasone and 5-fluorouracil from poly(ortho ester). Int J Pharm 1999 20;185(2):189-98.Google Scholar
  8. Graham PD, Brodbeck KJ, McHugh M. Phase inversion dynamics of PLGA solutions related to drug delivery. J Control Release 58: 233 - 45, 1999.PubMedCrossRefGoogle Scholar
  9. Grinnell BV. Recombinant Human Protein C. Presentation at IBC’s Advances in Anticoagulant, Antithrombotic and Thrombolytic Drugs, Boston, 1999.Google Scholar
  10. Gupta S, Moussy F, Dalby RN, Miekka SI, Bruley DF. Pulmonary delivery of human protein C and factor IX. Adv Exp Med Biol, 411, 429 - 35, 1997.PubMedCrossRefGoogle Scholar
  11. Heller J, Barr J, Ng SY, Shen HR, Schwach KA, Emmahl S, Rothen AW, Gurny R. Poly(ortho esters) — their development and some recent applications. Eur. J. Pharm. Biopharm., 50, 121 - 128, 2000.PubMedCrossRefGoogle Scholar
  12. Jeong B, Bae YH, Kim SW. In situ gelation of PEG-PLGA-PEG triblock copolymer aqueous solutions and degradation thereof. JBiomed Mater Res 50: 171 - 7, 2000.Google Scholar
  13. Mann KG, Bovill EG. Protein C deficiency and thrombotic risk. In “Advances in applied biotechnology series 11: Protein C and related anticoagulants”, Ed: Bruley DF and Drohan WN, Portfolio Publ. Co., Texas.Google Scholar
  14. Mao H, Kadiyala I, Leong KW, Zhao Z, Dang W. Biodegradable polymers: poly(phosphoester)s. In “Encyclopedia of Controlled Drug Delivery”, 1999 Vol. 1, Ed. E. Mathiowitz, Wiley-Interscience, p. 4560,.Google Scholar
  15. Minford AM, Parapia LA, Stainforth C, Lee D. Treatment of homozygous protein C deficiency with subcutaneous protein C concentrate. Br J. Haematol., 93, 215 - 6, 1996.PubMedCrossRefGoogle Scholar
  16. Nizzi FA, Kaplan HS. Protein C and S deficiency. Sem. Thromb. Hemostas. 25 265-277, 1999.Google Scholar
  17. Odegaard OR, Try K, Anderson TR. Protein C: An automated activity assay. Haemostasis 17, 109 - 113, 1987.PubMedGoogle Scholar
  18. Okumu FW, Daugherty A, Dao L, Fielder PJ, Brooks D, Sane S, Cleland JL. Sustained delivery of human growth hormone from a novel injectable liquid, PLAD. Proceed. Intl. Symp. Control. Rel. Bioact. Mater. 28, 1029 - 1030, 2001.Google Scholar
  19. Rogy H. (Baxter Immuno Hyland Division), Personal Communication,1999.Google Scholar
  20. Sanz-Rodriguez C, Gil-Fernandez JJ, Zapater P, Pinilla I, Granados E, Gomez-G de Soria V, Cano J, Sala N, Fernandez-Ranada JM, Gomez-Gomez N. Long-term management of homozygous protein C deficiency: replacement therapy with subcutaneous purified protein C concentrate. Thromb. Haemost., 81, 887 - 90, 1999.Google Scholar
  21. Schwarz HP, Schramm W, Dreyfus M. Monoclonal antibody purified protein C concentrate: Initial clinical experience. In “Advances in applied biotechnology series 11: Protein C and related anticoagulants”, Ed: Bruley DF and Drohan WN, Portfolio Publ. Co., Texas, 1990.Google Scholar
  22. Suzuki K. Protein C, In “Molecular Basis of Thrombosis and Hemostasis” Eds: High K. A. and Roberts H. R., Marcel Dekker, New York, 1995.Google Scholar
  23. Yalkowsky, S. H., Krzyzaniak, J. F., Ward, G. H. Formulation-related problems associated with intravenous drug delivery. J Pharm. Sci. 87, 787 - 796, 1998.PubMedCrossRefGoogle Scholar
  24. Yewey, G. L.; Duysen, E. G.; Cox, S. M.; Dunn, R. L. Delivery of proteins from a controlled release injectable implant. Pharm. Biotechnol. 10, 93 - 117, 1997.PubMedCrossRefGoogle Scholar
  25. Zambaux MF, Bonneaux F, Gref R, Dellacherie E, Vigneron C. Preparation and characterization of protein C-loaded PLA nanoparticles. J. Controlled Release, 60, 179 - 88, 1999.CrossRefGoogle Scholar
  26. Zhao Z, Chaubal MV, Su G, Jiang T, Dang W. In vitro degradation of polilactofates — a copolymer of lactide and phosphate. Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 27, 2000.Google Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Mahesh V. Chaubal
    • 1
  • Zhong Zhao
    • 2
  • Duane F. Bruley
    • 1
  1. 1.University of Maryland Baltimore CountyBaltimoreUSA
  2. 2.Guilford PharmaceuticalsBaltimoreUSA

Personalised recommendations